Amgen Inc. (AMGN)

186.59
0.59 0.32
NASDAQ : Health Technology
Prev Close 185.99
Open 186.31
Day Low/High 184.89 / 188.09
52 Wk Low/High 163.31 / 201.23
Volume 144.44K
Avg Volume 3.17M
Exchange NASDAQ
Shares Outstanding 661.71M
Market Cap 123.41B
EPS 2.70
P/E Ratio 59.21
Div & Yield 5.28 (2.65%)

Latest News

The New #41 Most Shorted Nasdaq 100 Component: Amgen

The New #41 Most Shorted Nasdaq 100 Component: Amgen

The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label

KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months

European Commission Approves Prolia® (denosumab) For Patients With Glucocorticoid-Induced Osteoporosis

European Commission Approves Prolia® (denosumab) For Patients With Glucocorticoid-Induced Osteoporosis

Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures

Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

THOUSAND OAKS, Calif., June 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39 th Annual Global Healthcare Conference at 9:30 a.

Amgen, Oklahoma Health Care Authority And University Of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes

Amgen, Oklahoma Health Care Authority And University Of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes

Amgen's First Public-Private Partnership with a State Medicaid Agency to Help Improve Patient Health Care Needs Through Data, Science and Information

Dow Finishes Slightly Lower as Nasdaq Jumps to Another Record Close

Dow Finishes Slightly Lower as Nasdaq Jumps to Another Record Close

Stocks are mixed Tuesday but traders continue to snap up tech stocks.

Nasdaq's on Fire: Cramer's 'Mad Money' Recap (Monday 6/4/18)

Nasdaq's on Fire: Cramer's 'Mad Money' Recap (Monday 6/4/18)

Jim Cramer talks about the stocks and sectors behind the resurgence fueling the Nasdaq's gains.

Jim Cramer: Move Over FANG, Long Live INJFANG

Jim Cramer: Move Over FANG, Long Live INJFANG

The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Jim Cramer says the market like this economy; he has your game plan for next week.

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 Mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 Mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 Mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 Mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma

Less Frequent Once-Weekly KYPROLIS Regimen Also Significantly Increased Overall Response Rates With a Comparable Safety Profile Versus a Twice-Weekly Regimen

Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers

Efforts to Focus on Pre-Clinical and Clinical Research for up to 16 Early-Stage Programs Across Various Types of Cancer

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMGN, CIG.C, COTV, CTRE, GMS, HPT, IAG, NFEC, QGEN, SCVL, THR, TPHS, USFD, UVV Downgrades: BKE, IGT, TSLX, VRX Initiations: MGEN Read on to get TheStreet Quant Ratings' detailed report:

Emboldened By Biotech Names

Emboldened By Biotech Names

For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment

Public-Private Partnership Aims to Connect Underserved Cancer Patients to Enhanced Symptom Management Support Through the Use of Connected Technologies

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Here's what you need to know now for Friday, May 18.

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.

FDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention

Migraine is a Severe Neurologic Disease That Profoundly Impacts Millions of Patients in the United States

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

New Indication Supports Amgen's Commitment to Reduce the Risk of Recurrent Cardiovascular Events Faced by Heart Attack and Stroke Survivors

Amgen Becomes #44 Most Shorted Nasdaq 100 Component, Replacing Ulta Beauty

The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Jim Cramer weighs in on Waste Management, Blackstone Group, Xilinx, Celgene, Nvidia, Exelixis, Moneygram and more.

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Jim Cramer thinks that, finally, bargain hunters are just saying, "Enough already! It can't be that bad."

Teva Shows Progress on Restructuring But Investors Want More

Teva Shows Progress on Restructuring But Investors Want More

The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.

Jim Cramer: Are Markets Getting Tired of Trump, Trade and Tariffs?

Jim Cramer: Are Markets Getting Tired of Trump, Trade and Tariffs?

Sooner or later, bargain hunters will say: 'Enough already. It can't be that bad.'

Haters Gonna Hate: Cramer's 'Mad Money' Recap (Wednesday 5/2/18)

Haters Gonna Hate: Cramer's 'Mad Money' Recap (Wednesday 5/2/18)

We have a wall of worry to overcome, but it's important to hear the other side of the trade, says Jim Cramer. Take Apple and Facebook, for example.

TheStreet Quant Rating: B (Buy)